Latvija - latviešu - Zāļu valsts aģentūra

fresenius kabi polska sp.z o.o., poland - vankomicīns - pulveris infūziju šķīduma koncentrāta pagatavošanai - 500 mg

Latvija - latviešu - Zāļu valsts aģentūra

sandoz gmbh, austria - amoksicilīns - apvalkotā tablete - 1000 mg

Latvija - latviešu - Zāļu valsts aģentūra

medical developments ned b.v., netherlands - metoksiflurāns - inhalācijas tvaiki, šķidrums - 99,9%

Latvija - latviešu - Zāļu valsts aģentūra

glaxosmithkline (ireland) limited, ireland - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 875 mg/125 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Latvija - latviešu - Zāļu valsts aģentūra

sifi s.p.a., italy - netilmicinum - acu pilieni, šķīdums vienas devas iepakojumā - 3 mg/ml

Latvija - latviešu - Zāļu valsts aģentūra

sifi s.p.a., italy - netilmicinum - acu pilieni, šķīdums - 3 mg/ml

Latvija - latviešu - Zāļu valsts aģentūra

sandoz gmbh, austria - amoksicilīns - apvalkotā tablete - 1000 mg

Latvija - latviešu - Zāļu valsts aģentūra

glaxosmithkline (ireland) limited, ireland - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 500 mg/125 mg